BioSpace News Archive

UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 for the treatment of advanced nonalcoholic steatohepatitis.

Astellas Pharma Inc. and Iveric bio, Inc. announced that on April 29, 2023, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.

Pliant Therapeutics, Inc. announced 24-week data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy and cetrelimab monotherapy in patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy.

As a next step in focusing on the US market The Board of Directors of Immunovia AB, has decided to appoint Jeff Borcherding, until now President of Immunovia’s US operation, as global CEO.